AMR Strategy

Entzündungen der Mundschleimhaut wie Gingivitis, Mukositis oder Schleimhautläsionen sind weit verbreitet und betreffen insbesondere ältere und chronisch kranke Menschen. Dennoch wird ihr Einfluss auf die Allgemeingesundheit häufig unterschätzt. Mit CANNEFF® DENTAL GEL steht nun eine innovative, antibiotikafreie Lösung zur Verfügung, die nicht nur entzündungshemmend und schmerzlindernd wirkt, sondern auch den aktuellen Anforderungen des österreichischen Gesundheitssystems entspricht. Der folgende Beitrag zeigt, warum CANNEFF® DNT GEL sowohl klinisch als auch gesundheitspolitisch eine hochrelevante Option darstellt – evidenzbasiert, verträglich und zukunftsorientiert.
Philip Schmiedhofer, MSc

Autor

Philip Schmiedhofer, MSc

Inhaltsverzeichnis

Importance of oral inflammations for the healthcare system

Inflammations in the oral cavity such as periodontitis, peri-implant mucositis, or mucosal lesions affect a large part of the population, especially older and chronically ill people.

CANNEFF® DNT GEL as a targeted solution for oral inflammations

CANNEFF® DNT GEL is a modern, CE-certified medical device for the targeted treatment of inflammatory and painful changes of the oral mucosa.

Contribution to the national AMR strategy: Effectiveness without antibiotics

The reduction of antibiotic use is a central concern of the Austrian healthcare system in line with the national AMR strategy.

Clinical evidence and therapeutic benefit

The effectiveness of CANNEFF® DNT GEL has so far been demonstrated in two clinical studies.

Market potential in Austrian primary care

With around 5,000 practicing dentists, dentistry is an important part of primary care in Austria.

Importance of Oral Inflammations for the Healthcare System

Inflammations in the oral cavity such as periodontitis, peri-implant mucositis, or mucosal lesions affect a large part of the population, especially older and chronically ill people. Despite their high prevalence, the impact of these diseases on general health is often underestimated. The World Health Organization (WHO) counts periodontal diseases among the most common chronic conditions worldwide. Their effects go beyond the oral area, as there are proven links to cardiovascular diseases and blood sugar control in diabetes. Products for treating oral inflammations therefore make a significant contribution to systemic healthcare.

CANNEFF® DNT GEL as a Targeted Solution for Oral Inflammations

CANNEFF® DNT GEL is a modern, CE-certified medical device for the targeted treatment of inflammatory and painful changes of the oral mucosa. It addresses a clinically relevant syndrome that occurs in the context of gingivitis, mucositis, mucosal lesions, or postoperative wound healing processes. The patented combination of cannabidiol (CBD) and squalane exerts antimicrobial and anti-inflammatory effects without the need for antibiotics. This makes the gel suitable both for dental use and for daily self-treatment at home.

Contribution to the National AMR Strategy: Effectiveness Without Antibiotics

Reducing antibiotic use is a central concern of the Austrian healthcare system in line with the national AMR strategy. Austria is involved in several EU-wide initiatives to curb antimicrobial resistance. CANNEFF® DNT GEL offers an evidence-based antimicrobial alternative. Its effect is achieved without antibiotics and thus actively supports the goals of AMR control—especially in the dental field, where systemic antibiotic administration should often be avoided.

Clinical Evidence and Therapeutic Benefit

The effectiveness of CANNEFF® DNT GEL has so far been demonstrated in two clinical studies. These showed significant relief of gingivitis, mucositis, and postoperative mucosal damage. Particularly noteworthy is its potential to prevent periodontitis. Due to its good tolerability, the gel is ideal for daily use, for example in implant care, for aphthae, to prevent periodontitis, or for follow-up care after dental procedures.

Market Potential in Austrian Primary Care

With around 5,000 practicing dentists, dentistry is an important part of Austrian primary care. At the same time, self-medication through pharmacies is gaining increasing importance. CANNEFF® DNT GEL is optimally suited for both areas. It can be recommended by doctors or obtained over the counter. As a CE-certified Class IIa medical device, it meets all regulatory requirements and has proven effectiveness, safety, and acceptance among patients.

Back to the blog
Philip Schmiedhofer, MSc

Philip Schmiedhofer, MSc

Medical Technician & Neuroscientist

Philip is the managing director and co-founder of cannmedic GmbH. With a degree in medical engineering and molecular biology, specializing in neuroscience and focusing on cannabinoids, he is recognized as an expert in the application of cannabinoids in medicine. As a medical device consultant, he leads the sales of cannmedic and offers specialized advice to medical professionals. His expertise includes the development and sales of cannabinoid-based products. In the field of research, he participates in significant basic research at the Center for Brain Research at the Medical University of Vienna. As co-founder and current managing director of cannhelp GmbH, a pioneer in the CBD sector, he has many years of entrepreneurial experience. Furthermore, he maintains an extensive network in the industry and advises internationally operating companies in the field of medical cannabinoids.